Won Ki Kang

TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.

TL;DR: This work uses gene expression data to describe four molecular subtypes linked to distinct patterns of molecular alterations, disease progression and prognosis in gastric cancer, and describes key molecular alterations in each of the four subtypes using targeted sequencing and genome-wide copy number microarrays.

TL;DR: Findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.

TL;DR: The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in Gastric cancer and a subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.

TL;DR: To the authors' knowledge, this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC and in pretreated patients, SLC is tolerated and significantly improves OS when added to BSC.